CTNNB1 and neoplasm: To explore the efficacy of ceritinib in a preclinical in vivo setting, we used an established patient-derived xenograft model, in which the highly proliferative and CTNNB1-mutated HB tumor PDX282 was subcutaneous propagated in immunocompromised mice.